Yes, please do come with something else. With the company failing and final inability to raise desperate funding, Naxos held onto the equity while institutions were selling? Crystal ball anyone. Throughout the failed SISP and subsequent liquidation? Any agreement they had would have clauses for milestones to achieve, financial worthiness, etc; not with BioAmbers precarious financial issues. Please provide proof of the above to justify your contention.
"Success is never final and Failure never fatal. It’s courage that counts."
George F. Tilton.